[1] |
Rouprêt M, Babjuk M, Compérat E, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update[J]. Eur Urol, 2018, 73(1): 111-122.
|
[2] |
Lughezzani G, Sun M, Perrotte P, et al. Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study[J]. Eur Urol, 2010, 57(6): 956-962.
|
[3] |
Li WM, Shen JT, Li CC, et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma[J]. Eur Urol, 2010, 57(6): 963-969.
|
[4] |
Seisen T, Colin P, Hupertan V, et al. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis[J]. BJU Int, 2014, 114(5): 733-740.
|
[5] |
Azmar MD, Comperat E, Richard F, et al. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance[J]. Urol Oncol, 2011, 29(2): 130-136.
|
[6] |
Catto JW, Hartmann A, Stoehr R, et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance[J]. J Urol, 2006, 175(6): 2323-2330.
|
[7] |
王安莲, 王勋, 刘赟, 等. 上尿路尿路上皮癌术后膀胱内复发的危险因素及预防性膀胱灌注化疗的意义[J]. 国际泌尿系统杂志, 2019, 39(3): 457-460.
|
[8] |
Freifeld Y, Ghandour R, Singla N, et al. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy[J]. Urol Oncol, 2020, 38(9): 737.e11-737.737.e16.
|
[9] |
Packiam VT, Leibovich BC, Thompson RH, et al. GEMINI: an open-label, single-arm, phase II trial of intraoperative gemcitabine intravesical instillation in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma[J]. J Clin Oncol, 2020, 38(6_suppl): TPS594.
|
[10] |
中国肿瘤医院泌尿肿瘤协作组. 非肌层浸润性膀胱癌膀胱灌注治疗专家共识(2021版)[J]. 中华肿瘤杂志, 2021, 43(10): 1027-1033.
|
[11] |
Kuroda M, Niijima T, Kotake T, et al. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer-the 6th trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40mg/40ml[J]. Eur Urol, 2004, 45(5): 600-605.
|
[12] |
孔垂泽, 刘奔, 李振华, 等. 预防肾盂输尿管癌术后再发膀胱癌的手术方法研究[J]. 中华泌尿外科杂志, 2006(4): 250-252.
|
[13] |
O'Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)[J]. Eur Urol, 2011, 60(4): 703-710.
|
[14] |
Wu P, Zhu G, Wei D, et al. Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and meta-analysis[J]. J BUON, 2015, 20(5): 1229-1238.
|
[15] |
李强. 单次与多次膀胱灌注化疗对上尿路尿路上皮癌术后复发膀胱癌的影响[J]. 国际泌尿系统杂志, 2020, 40(3): 481-484.
|
[16] |
苗淼, 孔垂泽, 李振华, 等. 减少肾盂癌术后再发膀胱癌的临床研究[J]. 中华外科杂志, 2009, 47(10): 728-730.
|
[17] |
Huang Y, Cen J, Liu Z, et al. A comparison of different prophylactic intravesical chemotherapy regimens for bladder cancer recurrence after nephroureterectomy for primary upper tract urothelial carcinomas: a retrospective 2-center study[J]. Technol Cancer Res Treat, 2019, 18: 1533033819844483.
|
[18] |
梁华民, 齐文旭, 张明. 上尿路尿路上皮癌手术后单次与多次膀胱灌注化疗对发生膀胱癌的影响[J]. 中国药物与临床, 2019, 19(5): 754-756.
|
[19] |
曹明, 马辰凯, 马俊, 等. 吉西他滨膀胱灌注治疗复发性浅表性膀胱肿瘤的安全性与有效性[J]. 中华肿瘤杂志, 2011, 33(5): 385-387.
|
[20] |
Messing EM, Tangen CM, Lerner SP, et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial[J]. JAMA, 2018, 319(18): 1880-1888.
|
[21] |
Leow JJ, Martin-Doyle W, Fay AP, et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma[J]. Eur Urol, 2014, 66(3): 529-541.
|
[22] |
Bajorin DF, Witjes JA, Gschwend J, et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)[J]. J Clin Oncol, 2021, 39(6_suppl): 391.
|
[23] |
Ye D, Liu J, Zhou A, et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma[J]. Cancer Sci, 2021, 112(1): 305-313.
|